Company news

Immunome, Inc. news in 2022

Immunome, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Immunome Reports Third Quarter 2022 Financial Results

November 13, 2022

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

November 8, 2022

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

August 22, 2022

Immunome Reports Second Quarter 2022 Financial Results

August 4, 2022

Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1

July 5, 2022

Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

June 8, 2022

Immunome to Present at the Jefferies Healthcare Conference

June 1, 2022

Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

May 22, 2022

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

May 18, 2022

Immunome Reports First Quarter 2022 Financial Results

May 11, 2022

Immunome Reports Fourth Quarter and Full Year 2021 Financial Results

March 27, 2022

FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19

March 10, 2022

Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing

February 7, 2022

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

January 9, 2022

Decks in 2022